Is Regeneron Pharmaceuticals Inc’s Fuel For Real? The Stock Was Bought By Option Traders

 Is Regeneron Pharmaceuticals Inc's Fuel For Real? The Stock Was Bought By Option Traders

In today’s session Regeneron Pharmaceuticals Inc (REGN) registered an unusually high (980) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious REGN increase. With 980 contracts traded and 3404 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: REGN161118C00410000 closed last at: $17.1 or 1800% up. About 137,861 shares traded hands. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 6.78% since April 11, 2016 and is uptrending. It has outperformed by 0.63% the S&P500.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Ratings Coverage

Out of 19 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 9 rate it a “Buy”, 1 “Sell”, while 9 “Hold”. This means 47% are positive. $700 is the highest target while $300 is the lowest. The $562.67 average target is 34.94% above today’s ($416.98) stock price. Regeneron Pharmaceuticals Inc. has been the topic of 41 analyst reports since July 28, 2015 according to StockzIntelligence Inc. Credit Suisse initiated the shares of REGN in a report on Wednesday, January 20 with “Neutral” rating. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Outperform” rating by RBC Capital Markets on Thursday, November 5. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Buy” rating given on Friday, August 21 by Vetr. On Tuesday, February 16 the stock rating was upgraded by Chardan Capital Markets to “Neutral”. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, October 2. The rating was maintained by Chardan Capital Markets on Tuesday, August 4 with “Buy”. The firm has “Market Perform” rating given on Wednesday, April 20 by Wells Fargo. The firm has “Sell” rating by Chardan Capital Markets given on Monday, January 25. Leerink Swann maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rating on Monday, April 4. Leerink Swann has “Outperform” rating and $523 price target. Chardan Capital Markets maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Monday, November 7 with “Sell” rating.

According to Zacks Investment Research, “Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron’s platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)”

Insitutional Activity: The institutional sentiment increased to 1.19 in 2016 Q2. Its up 0.44, from 0.75 in 2016Q1. The ratio increased, as 51 funds sold all Regeneron Pharmaceuticals Inc shares owned while 154 reduced positions. 50 funds bought stakes while 193 increased positions. They now own 70.88 million shares or 9.49% less from 78.30 million shares in 2016Q1.
Moreover, Ipg Advsr Lc has 0% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 2,600 shares. The Michigan-based Arcadia Invest Mgmt Corp Mi has invested 0.01% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Gam Holding Ag last reported 12,687 shares in the company. Mathes, a New York-based fund reported 625 shares. Allsquare Wealth Mgmt Limited Liability accumulated 0.07% or 204 shares. Monetary Mngmt Group Incorporated, a Missouri-based fund reported 50 shares. The United Kingdom-based Aberdeen Asset Mgmt Public Ltd Company Uk has invested 0.02% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Fjarde Ap last reported 0.14% of its portfolio in the stock. Hightower Ltd Com has 3,332 shares for 0.01% of their US portfolio. Sands Mgmt Limited Co owns 2.66M shares or 2.87% of their US portfolio. Exxonmobil Mgmt Tx, a Texas-based fund reported 20,190 shares. Concert Wealth Mngmt has invested 0.04% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Asset Mgmt accumulated 1,109 shares or 0.08% of the stock. Plante Moran Finance Advisors Ltd reported 78 shares or 0.02% of all its holdings. State Street has 0.12% invested in the company for 3.09M shares.

Insider Transactions: Since May 17, 2016, the stock had 1 insider purchase, and 3 sales for $20.55 million net activity. Another trade for 4,413 shares valued at $1.70 million was made by Van Plew Daniel P on Tuesday, May 17. On Tuesday, May 24 RYAN ARTHUR F sold $396,640 worth of the stock or 1,000 shares. GOLDSTEIN JOSEPH L had sold 2,125 shares worth $903,125. Another trade for 64,731 shares valued at $23.55 million was bought by Sanofi.

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The company has a market cap of $44.46 billion. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It has a 60.74 P/E ratio. It commercializes medicines for eye diseases, high low-density lipoprotein cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases.

REGN Company Profile

Regeneron Pharmaceuticals, Inc., incorporated on January 11, 1988, is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. The Firm commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. The Company’s marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. The Firm has over 10 product candidates in clinical development. These consist of Trap clinical programs and over 10 human monoclonal antibody product candidates. The Firm has generated each of the antibodies using its VelocImmune technology. The Company’s ARCALYST (rilonacept) Injection for subcutaneous Use is available in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children over 12 year.

More news for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) were recently published by: Fool.com, which released: “Regeneron Pharmaceuticals, Inc. Dropped 14.3% in October — Here’s Why” on November 08, 2016. Fool.com‘s article titled: “Better Buy: Regeneron Pharmaceuticals, Inc. vs. Roche Holding AG” and published on October 13, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment